Pharmacological dopamine (DA) replacement with Levodopa (L-DOPA) is the gold standard treatment for Parkinson's disease (PD). However, long term L-DOPA treatment is complicated by eventual debilitating abnormal involuntary movements termed L-DOPA induced dyskinesia (LID), a clinically significant obstacle for the majority of patients who rely on L-DOPA to alleviate PD-related motor symptoms. The manifestation of LID may in part be driven by excessive extracellular DA derived from L-DOPA, but potential involvement of DA reuptake in LID severity or expression is unknown. We recently reported that in 6-OHDA-lesioned striatum, norepinephrine transporter (NET) expression increases and may play a significant role in DA transport. Furthermore, L-DOPA preferentially inhibits DA uptake in lesioned striatum.
INTRODUCTION
Parkinson's Disease (PD) is the most common neurodegenerative movement disorder and its incidence is likely to only increase with the impending growth of the aging population (Siderowf and Stern, 2003) . PD is primarily characterized by the loss of dopamine (DA) neurons in the substantia nigra pars compacta. Therapeutically, the primary loss in nigral dopamine necessitates its replacement through the exogenous administration of L-DOPA, a dopamine precursor or with DA agonists (Hornykiewicz and Kish, 1987; Steiger and Quinn, 1995) . L-DOPA in particular, has remained the drug of choice for treating PD for nearly half a century (Calne and Sandler, 1970) . Despite the ability of L-DOPA to significantly improve motor function, it is not without considerable side effects that severely limit its use long-term. L-DOPAinduced dyskinesia (LID) is a debilitating movement disorder brought on by chronic L-DOPA use. Approximately 90% of patients within the first 10 years of treatment develop LID (Ahlskog & Meunter 2001; Marsden, 1994; Mones et al., 1971; Olanow and Koller, 1998) . Not only is the onset of dyskinesia a significant setback for the patient, its presence is often permanent, occurring with every subsequent exposure to L-DOPA, which limits the clinical efficacy of what has long been considered our gold standard in PD treatment.
Evidence suggests chronic L-DOPA leads to major adaptive molecular changes occurring within the basal ganglia that may underlie LID pathophysiology (for review see Cenci and Konradi, 2010) . Loss of nigrostriatal dopaminergic neurons not only impairs pre-synaptic control of DA regulation, but also leads to large variances in extracellular levels of DA that parallel L-DOPA dosing regimens (Cenci and Lundblad, 2006) . It is these supra-physiological fluctuations in extracellular DA content that are thought to underlie the induction of L-DOPA induced dyskinesia (Chase, 1998) . LID has been associated with plastic changes in postsynaptic neuronal targets within the striatum, including abnormal trafficking of the DA D1
receptor (Berthet et al., 2009; Guigoni et al., 2007) . This has also been shown clinically as well:
M O L # 9 3 3 0 2 5 positron emission tomography (PET) imaging studies reveal an association between peak-dose dyskinesia with abnormally high levels of synaptic DA in the caudate-putamen of L-DOPA induced dyskinetic patients (de la Fuente-Fernandez et al., 2004; Pavese et al., 2006) . In line with these studies, pre-clinical data show that dyskinetic rats exhibit higher levels of extracellular DA after L-DOPA administration than those seen in non-dyskinetic animals (Meissner et al., 2006; Lindgren et al., 2010) . These data raise the possibility that not only does striatal extracellular DA play a pivotal role in the onset of dyskinesia, but could be the triggering element of the post-synaptic alterations identified in both clinical and pre-clinical models.
However, despite considerable efforts directed at delineating the role L-DOPA plays in altering dopaminergic striatal signaling, the exact mechanism of how this occurs remains conflicting and inconclusive (Cenci & Konradi 2010) .
In PD, the loss of the dopamine transporter (DAT) likely impairs its ability to maintain DA bioavailability, yet most studies indicate motor symptoms are seen only when ~70% of striatal DAT is lost (Bernheimer et al., 1973; Bezard et al., 2001) , indicating an alternate mechanism through which DA may still be effective to produce normal locomotion. Indeed, many studies have concluded that serotonergic terminals may transport L-DOPA or DA, and subsequently release DA in order to maintain DA signaling, albeit in a dysregulated fashion (Arai et al., 1995; Miller and Abercrombie et al., 1999; Tanaka et al., 1999; Kannari et al. 2001 , Carta et al., 2007 .
However, it is a comparatively neglected observation that in sparsely dopaminergic innervated regions, such as the frontal cortex, the norepinephrine transporter (NET) can also transport DA (Moron et al., 2002) , and NE uptake inhibitors which can result in increased extracellular DA levels within the prefrontal cortex (Carboni et al., 1990; Di Chiara et al., 1992; Tanda et al., 1997; Gresch et al., 1995; Masana et al., 2012; Yamamoto and Novotney, 1998; Wayment et al., 2001) . In line with these observations, we have recently reported that DA transport still occurs in the 6-OHDA-lesioned striatum, despite major loss of DAT, and that a potential role for M O L # 9 3 3 0 2 6 NET in DA uptake is evident (Chotibut et al., 2012) . In these experiments, L-DOPA preferentially inhibits DA reuptake when striatal DAT loss exceeds the level necessary for PD symptom appearance, and preferentially inhibits norepinephrine over DA uptake in striatal tissue. Therefore, based upon these observations, chronic L-DOPA could exacerbate the L-DOPA induced-dysregulation of synaptic DA by its influence on a NET-dominated regulation of DA uptake that evolves with the gradual loss of DA terminals.
In an effort to further explore this possibility, we examined how the blockade of NET in a chronic desipramine (DMI) paradigm would affect dyskinesia expression, NET expression, DA uptake, and an established post-translational event in striatum associated with dyskinesia, extracellular signal-regulated protein kinase phosphorylation (ppERK), in an established 6-OHDA LID rodent model.
MATERIALS and METHODS:

Animals
Male Sprague Dawley rats purchased from Charles-River were used in all experiments.
A total of 21 test subjects were used at the start of the study, were 4-8 months of age, and were housed 1 per cage and under controlled lighting conditions (12:12 light:dark cycle) with food and water available ad libitum. All animals were used in compliance with federal and the institutional Animal Care and Use Committee guidelines at LSU Health Sciences Center-Shreveport. All behavioral testing was performed between 10:00 and 16:00 h. Behavioral data obtained from test subjects that did not have >70% TH loss, as discovered after completion of LID assessments and tissue analysis, was excluded from the results. We note that protein recovery was limited in some rats due to the fact we analyzed DA uptake, TH, NET, tERK, and ppERK all from the same striatal tissues and as such, the treatment group numbers are not of equal size.
In all experiments, rats were rendered briefly unconscious with isoflourane and immediately decapitated on day 40 of the experiment (1 day post last behavioral test and treatment (L-DOPA + DMI, L-DOPA or vehicle) for dissection of striatal tissues.
6-OHDA Lesions
Rats were anesthetized with 40 mg/kg Nembutal intraperitoneal (i.p.) (pentobarbital Lundbeck Inc, Deerfield, IL) with supplement of 9.0, 0.6, and 0.3 mg/kg ketamine, xylazine, and acepromazine, respectively. Each animal then underwent survival surgery to deliver the neurotoxin 6-OHDA unilaterally to the medial forebrain bundle while immobilized in a stereotaxic frame (coordinates ML +1.5, AP -3.8, DV -8.0 relative to Bregma). All stereotaxic coordinates are cited according to the stereotaxic atlas of Paxinos and Watson rat brain atlas, 4 th ed.
(Academic Press, 1998). A total of 16 µg of 6-OHDA in a total of 4 µl in 0.02% ascorbic acid (concentration of 4 mg/ml) was infused unilaterally at a rate of 1 µl/minute. The contralateral medial forebrain bundle was infused with vehicle (.02% ascorbic acid) and infused at the same rate and coordinates. The syringe was left in place for 10 min before removal to allow for maximal diffusion of drug and to avoid further mechanical damage to the tissue. Body temperature was maintained at 37º during surgery using a temperature monitor with probe and heating pad (FHC, Bowdoingham, ME). Animals were kept warm after surgery and monitored closely after anesthesia. In our hands (Chotibut et al., 2012 , Fig 7) ), we have previously shown that after 6-OHDA infusion, there was no significant difference in lesioned striatal tissue NE content compared to contralateral striatum and as such, have based these experiments from these observations. As such, we did not pre-treat these rats with DMI.
Amphetamine Testing
The extent of the lesion was evaluated 7 days post-surgery based on the net ipsilateral rotations measured over a 60 minute period following an injection of 2.5 mg/kg D-amphetamine and Arbuthnott, 1970) . 100 net full turns on the ipsilateral side to the lesion was necessary to be included in the study. In our hands, we have established this time frame as enough to consistently catch >60% of TH loss (Chotibut et al., 2012; 2014; Salvatore, et al., 2014) . Ultimately however, post-mortem verification of the lesion severity was determined by assessment of tyrosine hydroxylase protein as previously reported (Chotibut et al., 2012; 2014) . And thus, any further exclusions were due to rats that did not also have >70%
TH loss after western blot analysis at the end of the study. The behavioral AIMS data reflects test subjects with >70% TH protein loss.
Desipramine and L-DOPA Administration
9 days post lesion, rats were randomly divided into 3 groups. 2 groups received a treatment of DMI (Tocris, cat #3067) (12mg/kg) and 1 group received Vehicle (.9% saline 12mg/kg) i.p for 30 consecutive days. Then, at 19 days post lesion, an additional treatment of either L-DOPA (12mg/kg) and Benserazide-hydrochloride (15mg/kg) or Vehicle (.9% saline) was given once daily for 20 consecutive days (Fig 1) . In summary, 3 treatment groups were created:
(1) DMI Pretreatment + L-DOPA/Benserazide, (2) Vehicle Pretreatment + L-DOPA/Benserazide and (3) DMI Pretreatment + Vehicle (0.9% NaCl Saline, Hospira, Lake Forest, IL). With 6-OHDA lesion present in each group, these three groups were used to evaluate the impact of DMI on LID behavior caused by chronic L-DOPA, with the DMI alone group controlling for whether NET-blockade alone could produce LID.
Behavioral AIMS ratings
L-DOPA-induced abnormal involuntary movements (AIMs) were then rated at 6 discrete time points (days 19, 23, 27, 31, 35, 39) during the 20-day administration of L-DOPA starting on day 19-post lesion until the end of the study. AIMs were assessed by an investigator blind to treatment. Twenty minutes after L-DOPA administration, rats were placed in separate cages M O L # 9 3 3 0 2 9 and individual dyskinetic behaviors were quantified based on severity and frequency during a 1-minute observation period performed every 20 minutes over a period of 160 minutes. AIMs were classified into three subtypes as follows: axial AIMs (dystonic posturing of the upper trunk towards the side contralateral to the lesion), limb AIMs (hyperkinetic or jerky movements of the forelimb contralateral to the lesion), and orolingual AIMs (abnormal jaw movements, facial twitching and tongue protrusion). Each subtype was scored based on severity and frequency from 0 to 4, with 4 being the most severe and/or occurring continuously during the entire 1-minute observation period (for review, see Cenci et al., 1998 and Lundblad et al., 2004) . Global AIMs scores were calculated by multiplying the severity score x frequency score for each observation period and combining the scores on all monitoring periods. Theoretically, the highest AIMs score achievable in one behavioral test day (with 8 observation periods) would be 384.
Preparation of Synaptosomes
In order to ascertain uptake properties in conjunction with protein and protein phosphorylation expression levels present in the rats immediately following the last LID assessment, synaptosomes were prepared according to the protocol previously described (Salvatore et. al. 2003) with the following modifications: Tissue dissected from dorsal striatum was homogenized in 5 mL of 0.32 M sucrose solution using a Teflon/glass homogenizing wand (Glas-Col, Terre Haute, IN) then spun at 1000 x g for 10 minutes in a chilled (4° C) centrifuge.
The resulting pellet was stored as the P1 fraction while the supernatant was spun further at 16,500 x g for 30 minutes at 4° C, yielding the P2 fraction. An aliquot of the P1 fraction was saved for determination of TH protein, ppERK, and total ERK protein from the 6-OHDA-lesioned and contralateral (control) striatum against a standard curve of TH protein standard (Salvatore M O L # 9 3 3 0 2 1 0 precise assessment of cytosolic proteins (Chotibut et al., 2012 (Chotibut et al., , 2014 , reflecting the relative quantities recovered in fresh frozen preparations (Salvatore et al., 2009 ). An aliquot of P2 fraction was saved for determination of NET protein from the 6-OHDA lesioned and contralateral (control) striatum. The supernatant was aspirated and resuspended in 1 mL of Kreb's buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 25 mM NaHCO3, 1.0 mM Na2EDTA, 1.7 mM CaCl2, 10 mM glucose, 100 μ M parglyline, 100 μ M ascorbic acid). Protein concentration was determined using a BCA colormetric assay (Thermo Scientific, Rockford, IL). All tissue was kept on ice or at 4 °C from the moment of brain excision until the uptake assay took place.
[
H]DA uptake into Synaptosomes
Synaptosomes were distributed in ice-cold test tubes to prepare for DA uptake. The determination of [ 3 H]DA uptake in the crude synaptosomes from dorsal striatum harvested from the contralateral and 6-OHDA-infused hemispheres was conducted simultaneously and included assessments of DA uptake capacity in the presence of unlabeled 1 µM NE and DA. We previously determined that this concentration of NE or DA had differential impact on DA uptake (Chotibut et al., 2012) and consistent with previous observations. Each determination was done in triplicate for each assay condition and uptake was determined comparing the lesioned striatum with the contralateral control striatum. Non-specific uptake was determined by counts obtained in synaptosomes incubated with 500 nM DA (all as labeled DA) on ice during the time period of uptake. Background was determined and subtracted in the same manner as in the DA uptake studies. Sabeti et. al. (2002) and where differences in uptake capacity between lesioned and intact striatum have been previously reported (Chotibut et al., 2012) . Synaptosomes were washed extensively to remove excess labeled-dopamine with equal-osmolarity PBS buffer through a Brandel M24-TI (Gaithersburg, MD) cell harvester using Brandel GF/C filter paper pretreated with a 2% polyethylenimine solution to reduce non-specific binding of label. The filter paper containing the rinsed synaptosomes was transferred into scintillation vials containing 5 mL of biodegradable scintillation cocktail (Research Products International, Mount Prospect, IL) and counted with a Beckman Coulter LS6500 scintillation counter (Brea, CA).
Calculating DA uptake
To determine the quantity of DA uptake, the percent of 
Analyses of proteins and ERK phosphorylation
Synaptosome fraction (P1) and the processed preparatory sample (P2) were sonicated in a 1% sodium dodecyl sulfate solution (pH ~8) using a Branson Sonifier 150 (Danbury, CT).
Protein concentration was determined using the bicinchoninic acid colormetric assay.
Following gel electrophoresis, proteins were transferred for 500 volt hours in a
Tris/glycine/methanol buffer onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA).
The nitrocellulose membrane was stained with Ponceau S to further normalize staining in each sample lane. These lanes were scanned and quantified by Image J to normalize protein in each sample. This relative total level then served as an additional normalizing value to determine the quantity of each protein assayed (Salvatore et al., 2012) . To continue processing, the membranes were blocked in PVP buffer (1% polyvinylpyrrolidone and 0.05%
Tween 20) for a minimum of two hours to reduce nonspecific antibody binding. The membrane was soaked in primary antibody for 1-3 hours. Specific primary antibodies were as follows: NET (Alpha Diagonistics, cat NET11-A) and TH (Millipore, cat #AB152), D1 receptor (Santa Cruz, cat #14001), ERK1/2 (Millipore cat #442704), ppERK1/2 (Sigma, cat #M8159). Protein loads for linear detection were 50ug total protein for NET, 10ug for TH and total ERK1/2, and 40ug for D1 and ppERK1/2. After primary treatment, blots were exposed to secondary antibody (swine antirabbit IgG for TH and NET) signal enhancement, followed by 1 hour incubation with [ 125 I] protein A (PerkinElmer, Waltham, MA).
Statistical Analysis
Data were analyzed using SPSS (Chicago, IL, USA) with correction for multiple comparisons and p-values < 0.05 considered significant. A two-way ANOVA (time x treatment) was used to analyze AIM scores over time within each session. Total AIM scores (axial + limb + oral (ALO)) summed across the 160-minute sessions were analyzed by two-way ANOVA. Oneway ANOVA and t-paired student tests were used in instances with more than 3 or more groups or 2 groups, respectively. One-way ANOVA analyses was followed by Post-Hoc Tukey multi-
Surgeries were performed in triplicates with the assumption that any irregularities in efficacy of the 6-OHDA lesion may occur in all animals lesioned with the same 6-OHDA on that day. Specifically, surgeries were performed in multiples of three each day to accommodate for the three treatments (L-DOPA, L-DOPA + DMI, DMI). Thus, any variances that may be encountered on each day that may affect lesion severity is assumed to occur to each rat on that given date of surgery. Additionally, the data was also analyzed using a paired t test when comparing contralateral and lesioned striatum or one way ANOVA between the 3 treatment groups.
Due to no dyskinesia elicited in DMI treatment group alone, area under the curve dyskinesia values (Fig 3A, B ) plots only included DMI + L-DOPA and L-DOPA treatment groups.
As such, a paired t-test ( Fig 3A) was performed to examine for differences in dependent measures between these two treatments as well as regression analyses to determine if LID differed over the course of L-DOPA treatment ( Fig 3B) .
RESULTS: LID severity increases with desipramine (DMI) pretreatment + L-DOPA compared to L-
DOPA alone
L-DOPA-induced abnormal involuntary movements (AIMs) were rated at 6 discrete time points (days 19, 23, 27, 31, 35 , 39 post 6-OHDA lesion, or days 1, 5, 9, 13, 17, 21 of daily L-DOPA) during the 20-day administration of L-DOPA starting on day 1 (19 days post 6-OHDA lesion). As L-DOPA treatment duration increased, the norepinephrine transporter inhibitor, desipramine (DMI), exacerbated dyskinesia expression in 6-OHDA lesioned male Sprague
Dawley rats compared to L-DOPA alone beginning on day 27 and through day 39 post-6-OHDA lesion induction (Fig 2A-F) . However, on day 19, when the first dose of L-DOPA was administered, DMI significantly attenuated LID severity (Fig 2A) . However, this attenuation of Additionally, LID severity did not change over time in the L-DOPA alone group.
However, in the L-DOPA+DMI group there was a significant increase in dyskinesia over the 20-day course of treatment with L-DOPA + DMI, with the severity increasing as the study progressed (Fig. 3B ).
Tyrosine Hydroxylase loss in treatment groups
There were no significant differences in tyrosine hydroxylase (TH) loss among the three treatment groups between lesioned and contralateral control striatum (Fig. 4A, B) . Therefore, the exacerbation of LID severity in DMI + L-DOPA treated rats most likely was not due to increased dopaminergic terminal destruction or lesion severity (L-DOPA: Average TH loss 80.2% + 4.9; DMI: 79% + 5.3; L-DOPA + DMI: 77% + 4.1).
Relative abundance of NET: lesioned vs. contralateral striatum
Either DMI alone or DMI + L-DOPA treatment significantly decreased NET abundance in the lesioned striatum compared to contralateral control striatum in the respective groups ( Fig   5A, B, D) . No difference in NET expression between control and lesioned striatum was observed in the L-DOPA group (Fig 5C, D) .
ERK phosphorylation in treatment groups
Levels of phosphorylated and total ERK1/2 were assessed in tissue fractions prepared from the 6-OHDA lesioned striatum from rats from each treatment group. Both antibodies revealed two bands with the expected molecular weights of ERK1 (44kDa) and ERK2 (42kDa).
Accounting for ppERK ½ in lesioned striatum, when compared to DMI alone, L-DOPA and DMI + L-DOPA treatment groups showed increased ppERK/ERK1 and ppERK/ERK2 ( Fig 6A, B respectively; representative western blot Fig 6E) . Interestingly, these changes were blunted in the control striatum (Fig 6C, D) . ppERK/ERK1 increased compared to DMI alone in both L-DOPA and L-DOPA + DMI treatments but there were no differences between L-DOPA and L-DOPA + DMI groups (Fig 6C) . Conversely, ppERK/ERK2 was increased only in L-DOPA treated rats compared to DMI (Fig 6D) . No differences were observed in total ERK between treatments (data not shown).
ERK phosphorylation and dyskinesia severity
The levels of ppERK1 are increased in L-DOPA preclinical studies (Santini et al., 2007; Westin et al., 2007) . We also observed a correlation between the severity of dyskinesia (as seen in the L-DOPA + DMI treatment group) and the ppERK1 signal, as measured in the lesioned striatum in each treatment group (Fig 7) , indicating that NET blockade in combination with L-DOPA may increase DA signaling associated with LID manifestation as observed at the end of the study (day 21 of L-DOPA). Specifically, simple regression of phospho-ERK1 levels
on the cumulative axial, limb and orolingual global AIM scores recorded from chronically L-DOPA, DMI + L-DOPA and DMI treated rats had a positive correlation with dyskinesia severity (Fig 7) .
DA uptake and NE inhibition
DA uptake was determined in synaptosomes from lesioned versus control striatal tissue in the presence of a concentration of DA or NE (1 µM) previously shown to differentially inhibit uptake of labeled [ 3 H]-DA (Chotibut et al., 2012) . In the L-DOPA group, we did not observe a significant difference in inhibition [ 3 H]-DA uptake by unlabelled DA between the lesioned and control striatum (% inhibition in control ~70%) (Fig. 8A ). However, NE inhibited DA uptake in lesioned striatum to a greater extent compared to that in control striatum (% inhibition in control ~50%) (Fig. 8B ). In the DMI + L-DOPA group, unlabelled DA did not differentially inhibit [ 3 H]-DA uptake between lesioned and control striatum (% inhibition in control ~70%) (Fig. 8C ).
However, NE was significantly less effective to inhibit DA uptake in lesioned compared to control striatum (% inhibition in control ~70%) (Fig. 8D) . NE also inhibited DA uptake to a significantly greater extent in lesioned striatum in the DMI alone group (data not shown).
DISCUSSION:
Dysregulation of extracellular (DA) in the DA-denervated Parkinsonian striatum is associated with LID (Carta et al., 2006; Cenci and Lundblad, 2006) . However, the relative contribution of DA uptake in LID onset or severity has not been established. The 6-OHDA lesion may increase striatal NET expression and NET may affect DA uptake therein (Chotibut et al., 2012) . In intact CNS tissue, such as prefrontal cortex, there is evidence for NET-mediated DA reuptake (Carboni et al., 1990; Tanda et al., 1997; Moron et al., 2002) . Accordingly, in lesioned striatum, the tissue content level of NE is comparable to that of DA (Chotibut et al.,
This article has not been copyedited and formatted. The final version may differ from this version. other DA regions like substantia nigra. DA uptake in the substantia nigra could also affect LID severity (Navailles et al., 2014) , given significant noradrenergic innervation in this region.
However, there is comparatively less DAT protein and DA uptake in the substantia nigra, which precluded us from examining this possibility.
L-DOPA may inhibit DA uptake in lesioned striatum (Chotibut et al., 2012; Hashimoto et al., 2005) , which could lead to accumulation of extracellular DA, and therefore affect LID onset or severity. Increased extracellular DA in DA-denervated striatum is observed following DMI (Arai et al., 2008) . This finding is congruent with our observations that reuptake of DA, derived from L-DOPA, may be modulated by NET. Thus, reducing NET function, either by L-DOPAblockade or reduced NET expression, could reduce DA clearance and exacerbate LID severity.
Accordingly, we found that NET inhibition (with DMI) and L-DOPA, gradually exacerbated LID severity over the 20-day course of L-DOPA administration, compared to L-DOPA alone (Fig. 3 ).
These differences in LID severity were unrelated to differences in lesion severity (Fig. 4) . Our previous finding that striatal NET expression increases at a comparatively earlier time point in lesion progression (Chotibut et al., 2012) , coupled with the present findings, give credence to involvement of NET in DA uptake and regulating LID expression or severity.
Our results also indicate that extracellular signal-regulated kinases 1 and 2 (ERK) phosphorylation was increased in the DMI + L-DOPA group compared to L-DOPA alone group (Fig. 6 ). Increased signaling through D1 receptors is implicated in the molecular and synaptic responses in striatal neurons associated with LID onset (Aubert et al. 2005; Konradi et al. 2004; Picconi et al. 2003; Westin et al., 2007) and enhanced ERK1/2 phosphorylation in DA denervated striatum occurs with selective agonists for D1 or D2 receptors (Cai et al. 2000;  M O L # 9 3 3 0 2 1 8 Pavon et al., 2006; Zhen et al. 2002) . Thus, increased ERK1/2 activity in striatal neurons is at the very least a biochemical marker of L-DOPA-induced dyskinesia through D1 or D2 overactivation. As such, phosphorylation of ERK1/2 may provide a molecular counterpart for increased D1 activity and be involved in LID induction. Reduced ERK1/2 phosphorylation dosedependently decreases LID and other molecular correlates causally linked to LID development (Santini et al., 2007) . Thus, the observation that DMI pretreatment with L-DOPA both exacerbates LID and increases ERK1/2 phosphorylation over that of L-DOPA alone supports a dopaminergic mechanism in LID severity wherein NET-mediated DA uptake and L-DOPA together modulate LID expression. Given that chronic DMI also reduced NET expression in lesioned striatum (Fig. 5) , this observation suggests that increasing NET function or expression could reduce LID severity.
Compensatory changes in DA regulation do occur during the loss of DA-regulating proteins in 6-OHDA rodent models (Snyder et al., 1990; Sarre et al., 2004; Perez et al., 2008) , but the potential involvement of NET function is a relatively novel concept. We have reported increased NET expression in lesioned striatum (Chotibut et al., 2012) . Increased locomotion is observed in monkeys with DAT inhibitors with high NET, but low serotonin transporter, affinity in cases of severe DAT loss (80%) compared to those with moderate DAT loss (46%) (Madras et al., 2006) . LID severity could also be diminished by other interactions with noradrenergic inputs to the basal ganglia (Lundblad et al., 2002; Dekundy et al., 2007; Gomez-Mancilla and Bedard 1993) . Furthermore, rats with combined noradrenergic and dopaminergic lesions have greater LID severity, compared to dopaminergic lesions alone (Fulceri et al., 2007; Shin et al., 2014) .
Indeed, noradrenergic lesions can produce dyskinesias through DA-mediated locomotor impairment (Donaldson et al. 1976 , Rommelfanger et al. 2007 ). As such, NET blockade via DMI may not be the only factor in worsening LID behavior. For example, in LID pathology, norepinephrine has the ability to act as a D1 dopaminergic agonist (Kubrusly et al., 2007) . Desipramine may also interfere with alternate receptors such as muscarinic, adrenergic and histamine. There is a functional interaction between the cholinergic and dopaminergic systems (Quik and Wonnacott 2011) , and DA denervation can increase acetylcholine levels in striatum. Given that acetylcholine mediates its effects via muscarinic and nicotonic receptors and that DMI may affect the sensitivity of post and/or pre-synaptic muscarinic receptors (Murugaiah and Ukponmwan, 2003) , it is possible DMI may be mediating its effects through muscarinic receptors, which may contribute to development of motor signs.
Behaviorally, we observe an initial delay in LID in the L-DOPA + DMI treatment group compared to L-DOPA, which may be related to increased NET expression with 6-OHDA lesion (Chotibut et al., 2012) . Therefore, this initial increase in NET in the lesioned compared to the contralateral unlesioned striatum may explain why dyskinetic behavior was not worsened on the first day of L-DOPA (day 19 post lesion) and that subsequent L-DOPA, in conjunction with DMI treatments, offset this increase in NET expression, revealing increased LID severity. Our DA uptake experiments (at the end of the LID assessment) also indicated that DA uptake is more inhibited by NE in the L-DOPA alone group, but less inhibited by NE in the DMI + L-DOPA group (Fig. 8) . We speculate that these differences may be related to NET expression.
Whereas, NET expression is not changed relative to control striatum in the L-DOPA group, it is decreased in the groups with DMI. Thus, this decrease in NE-sensitivity in DMI groups could be due to decreased NET availability in lesioned striatum. We also speculate that the lack of difference in NET expression in rats treated with L-DOPA alone may be due to increased NET with 6-OHDA lesion that is offset by possibility that L-DOPA could reduce NET expression over time. As such, this is an important unresolved question moving forward.
The cellular sources of NET are an important point of consideration. Noradrenergic innervation of dorsal striatum is relatively sparse, although NE levels are comparable with remaining DA in lesioned striatum (Chotibut et al., 2012) .
In prefrontal cortex, NET transports
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